JP2020514301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514301A5 JP2020514301A5 JP2019537110A JP2019537110A JP2020514301A5 JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5 JP 2019537110 A JP2019537110 A JP 2019537110A JP 2019537110 A JP2019537110 A JP 2019537110A JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- domain monomer
- monomer
- polypeptide
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443523P | 2017-01-06 | 2017-01-06 | |
| US62/443,523 | 2017-01-06 | ||
| PCT/US2018/012689 WO2018129397A1 (en) | 2017-01-06 | 2018-01-05 | Compositions and methods related to engineered fc-antigen binding domain constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514301A JP2020514301A (ja) | 2020-05-21 |
| JP2020514301A5 true JP2020514301A5 (https=) | 2021-02-18 |
Family
ID=62791385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537110A Pending JP2020514301A (ja) | 2017-01-06 | 2018-01-05 | 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200040084A1 (https=) |
| EP (1) | EP3565595A4 (https=) |
| JP (1) | JP2020514301A (https=) |
| AU (1) | AU2018205272A1 (https=) |
| CA (1) | CA3049426A1 (https=) |
| RU (1) | RU2019124709A (https=) |
| WO (1) | WO2018129397A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112912103B (zh) * | 2018-05-21 | 2025-08-29 | 广州邦定生物技术有限公司 | 多价蛋白质复合物 |
| US20210284717A1 (en) * | 2018-07-11 | 2021-09-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| CN113382749A (zh) * | 2018-07-11 | 2021-09-10 | 动量制药公司 | 与工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| CA3106212A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| US20210238310A1 (en) * | 2018-07-11 | 2021-08-05 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
| SG11202106353VA (en) * | 2019-02-26 | 2021-07-29 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| JP2022548925A (ja) * | 2019-09-18 | 2022-11-22 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＣＤ３８を標的とした改変されたＦｃ抗原結合ドメイン構築物に関する組成物及び方法 |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| KR20230060546A (ko) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219897A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| EP4700047A1 (en) | 2023-04-21 | 2026-02-25 | Centenaire Biosciences, Inc. | Antigen-binding protein containing two fc domains and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| WO2008137382A1 (en) * | 2007-04-30 | 2008-11-13 | Centocor, Inc. | Anti-tissue factor antibodies and compositions with enhanced effector function |
| AR085404A1 (es) * | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas de union a antigeno |
| JP5987057B2 (ja) * | 2011-07-27 | 2016-09-06 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン |
| HK1220465A1 (zh) * | 2013-03-06 | 2017-05-05 | Merrimack Pharmaceuticals, Inc. | 抗c-met串联fc双特异性抗体 |
| US10858417B2 (en) * | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP4299595A3 (en) * | 2014-05-02 | 2024-03-13 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
-
2018
- 2018-01-05 WO PCT/US2018/012689 patent/WO2018129397A1/en not_active Ceased
- 2018-01-05 US US16/474,572 patent/US20200040084A1/en not_active Abandoned
- 2018-01-05 EP EP18735797.5A patent/EP3565595A4/en not_active Withdrawn
- 2018-01-05 JP JP2019537110A patent/JP2020514301A/ja active Pending
- 2018-01-05 RU RU2019124709A patent/RU2019124709A/ru unknown
- 2018-01-05 CA CA3049426A patent/CA3049426A1/en not_active Abandoned
- 2018-01-05 AU AU2018205272A patent/AU2018205272A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514301A5 (https=) | ||
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| JP2018046872A5 (https=) | ||
| JP2023052214A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| JP2021098732A5 (https=) | ||
| JP2016505556A5 (https=) | ||
| JP2022519118A5 (https=) | ||
| JP2020022482A5 (https=) | ||
| ES2533963T3 (es) | Composiciones farmacéuticas dirigidas a receptores Erb-B1 | |
| JP2017504577A5 (https=) | ||
| JP2021532085A5 (https=) | ||
| JP2022545647A5 (https=) | ||
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2010538608A5 (https=) | ||
| RU2013141956A (ru) | Антитело против ксф-1r | |
| JP2019534277A5 (https=) | ||
| JP2018507188A5 (https=) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2023507729A5 (https=) | ||
| JP2010523592A5 (https=) | ||
| RU2017129236A (ru) | Мультивалентные молекулы, содержащие dr5-связывающие домены | |
| JP2021515798A5 (https=) | ||
| JP2024512135A5 (https=) | ||
| JP2021531268A5 (https=) |